You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS<br />
Corporate Structure<br />
Head Of fice: Novartis<br />
CH-4002 Basel<br />
Swit zer land<br />
Tel: +41 (61) 324 1111<br />
Fax: +41 (61) 324 8001<br />
Home Page: www.novartis.com<br />
Ex ec u tive Com mit tee:<br />
Chair man & CEO: Dan iel Vasella<br />
CFO: Raymund Breu<br />
Head of Pharmaceuticals: Jo seph Jimenez<br />
Head of Con sumer Health: Thomas Ebeling<br />
Head of Sandoz: Andreas Rummelt<br />
Head of Vac cine and Di ag nos tics: Joerg Reinhardt<br />
Head of Bio med i cal Re search: Mark C Fishman<br />
Head of Hu man Re sources: Juergen Brokatzky-Gei ger<br />
Head of Cor po rate Af fairs: Thomas Wellauer<br />
Board of Di rec tors:<br />
Di rec tors: Dan iel Vasella<br />
Ulrich Lehner<br />
Hans-Joerg Rudloff<br />
Pe ter Burckhardt<br />
Srikant Datar<br />
Wil liam W George<br />
Alexandre F Jetzer<br />
Pi erre Landolt<br />
Andreas von Planta<br />
Wendelin Wiedeking<br />
Mar jo rie Yang<br />
Rolf M Zinkernagel<br />
Hon or ary Chair man: Alex Krauer<br />
Cor po rate Sec re tary: Bruno Heynen<br />
Source: Novartis An nual Re port 2007/Novartis 2008<br />
Note: In Oc to ber 2008, Novartis an nounced var i ous or ga ni za tional struc ture and man age ment changes.<br />
Joerg Reinhardt was ap pointed as the new COO. Re plac ing him as Head of Vac cines and Di ag nos tics is Dr<br />
Andrin Oswald, cur rently CEO of Speedel and Global Head of Phar ma ceu ti cal De vel op ment Fran chises. The<br />
Board has ap pointed George Gunn as the new Head of Con sumer Health in ad di tion to his cur rent role as<br />
Head of the An i mal Health busi ness unit. He will re place Thomas Ebeling, who is leaving Novartis.<br />
Andreas Rummelt will as sume the newly-cre ated po si tion of Group Head of Qual ity As sur ance and Tech ni cal<br />
Op er a tions and will re main a mem ber of the Ex ec u tive Com mit tee. Jeff George, cur rently Head of Emerg ing<br />
Mar kets in the Pharma Di vi sion, will re place him as the new Head of Sandoz. In ad di tion to his role as Head<br />
of the On col ogy busi ness unit in the Pharma Di vi sion, Da vid Ep stein will also lead a new unit fo cus ing on in -<br />
no va tive mo lec u lar di ag nos tics. These changes will be come ef fec tive on De cem ber 1, 2008. In ad di tion,<br />
Thomas Werlen, who serves as Gen eral Coun sel, was named a mem ber of the Executive Committee with<br />
immediate effect.<br />
It was also re ported that Wil liam George, a mem ber of the Novartis Board of Di rec tors, has de cided not to<br />
stand for re-elec tion at the next an nual share holder meet ing. At the next meet ing (sched uled for Feb ru ary<br />
2009), the Board will pro pose Dr Wil liam Brody, Pres i dent of The Johns Hopkins Uni ver sity and des ig nated<br />
Pres i dent of the Salk In sti tute, for election.<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 5
Change language